Company profile: SeraCare Life Sciences
1.1 - Company Overview
Company description
- Provider of products and services facilitating R&D and production of human and animal diagnostics and therapeutics, including diagnostic controls, plasma-derived reagents, molecular biomarkers, biobanking, clinical genomics NGS reference standards, infectious disease assay tools, immunoassay reagents, OEM biological materials for assay developers, NGS cancer profiling controls, and purified human blood fractions.
Products and services
- Infectious Disease Assay Tools: QC-focused serological and molecular panels delivering quality controls to validate, monitor, and ensure confidence in assay performance for infectious disease assays
- NGS Controls for Cancer Profiling Assays: Clinically-relevant reference materials containing DNA and RNA variants for NGS and PCR-based cancer tests in profiling assays
- NGS Reference Standards: Multiplexed clinical genomics reference standards offering a wide selection tailored for tumor profiling, NIPT, cell-free DNA, and germline sequencing applications in clinical genomics workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SeraCare Life Sciences
GlycoFi
HQ: United States
Website
- Description: Provider of biotherapeutic development based on glycan optimization technology and a yeast-based glycosylation protein manufacturing process, aiming to build its own pipeline of therapeutic proteins and partner with other drug-makers to develop products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoFi company profile →
Primerdesign
HQ: United Kingdom
Website
- Description: Provider of real-time PCR solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primerdesign company profile →
Ethypharm
HQ: France
Website
- Description: Provider of pharmaceutical products for the treatment of pains and addictions, designing, formulating, developing, manufacturing, and marketing them.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ethypharm company profile →
Ra Pharma
HQ: United States
Website
- Description: Provider of Cyclomimetics, a new drug class combining the diversity and specificity of antibodies with the benefits of small molecules; leveraging rapid generation of drug candidates to build a portfolio and partnerships focused on intracellular protein-protein interactions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ra Pharma company profile →
Breath Therapeutics
HQ: Germany
Website
- Description: Provider of inhaled investigational therapies for rare respiratory diseases, combining novel formulations of existing drugs with cutting-edge inhalation technology. Pipeline includes Liposomal Cyclosporine A for Inhalation for bronchiolitis obliterans syndrome to deliver drug to lungs while minimizing systemic exposure, and inhaled colistimethate sodium for non-cystic fibrosis bronchiectasis targeting Pseudomonas aeruginosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Breath Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SeraCare Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SeraCare Life Sciences
2.2 - Growth funds investing in similar companies to SeraCare Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SeraCare Life Sciences
4.2 - Public trading comparable groups for SeraCare Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →